Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant776 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06272240 | Tumor Microenvironment in Ovarian Cancer(MICO) | recruiting | — | 50 | University of UdineOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05983276 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | recruiting | Phase 2 | 40 | Loyola UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249308 | Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC ) | recruiting | — | 168 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05753826 | Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06232122 | Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer | recruiting | N/A | 45 | Chang Gung Memorial HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06229522 | Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).(PANDORA) | recruiting | — | 150 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06215950 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04716686 | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06188455 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | not yet recruiting | Phase 3 | 37 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT05446545 | Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer(EOC) | recruiting | — | 139 | Fudan UniversityOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05444270 | Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer(SABR-ROC) | recruiting | N/A | 270 | Yonsei UniversityOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | recruiting | Phase 2 | 40 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | active not recruiting | Phase 1 / Phase 2 | 523 | Mersana TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06032975 | PRO for Fighting FT in Ovarian Cancer(MITO45-ProFFiT) | recruiting | — | 240 | National Cancer Institute, NaplesOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06117384 | Systems Oncology Approach to Optimize Ovarian Cancer Treatment(ONCOSYS-OVA) | recruiting | — | 500 | University of HelsinkiOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06118307 | Shanghai Ovarian Cancer and Family Care Project | recruiting | — | 3,546 | Shanghai First Maternity and Infant HospitalOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06103916 | Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice(PRIORITY) | recruiting | — | 613 | Maxima Medical CenterOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06081595 | Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | not yet recruiting | Phase 2 | 54 | Jin LiOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06070285 | Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06063070 | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05794659 | Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer(Cornerstone4) | not yet recruiting | Phase 2 | 98 | Aston Sci. Inc.INDUSTRY | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05931055 | The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer | not yet recruiting | — | 1,000 | Peking Union Medical College HospitalOTHER | 0 | Jul 5, 2023 | clinicaltrials |
| NCT05833321 | Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer(SARCO-GYN) | recruiting | N/A | 75 | Centre Hospitalier Metropole SavoieOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05431530 | Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer(LAPSODY) | recruiting | — | 108 | Seoul National University HospitalOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05912972 | Development and Management of Registry in Patients With Gynecologic Cancer in Korea | recruiting | — | 13,500 | Asan Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04519151 | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | recruiting | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05606692 | Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)(anesthetics) | recruiting | Phase 4 | 416 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05251883 | A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics | recruiting | — | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05862740 | ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer(ULTRA-LAP) | recruiting | N/A | 62 | Azienda Ospedaliera di PadovaOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT03275194 | HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy | recruiting | Phase 2 | 100 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02429687 | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors(MOGCT-01) | recruiting | Phase 3 | 129 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02429700 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors(SCST-01) | recruiting | Phase 3 | 132 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03458221 | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER(STAPOVER) | recruiting | Phase 2 / Phase 3 | 148 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05810701 | FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer(FRAGINOC) | recruiting | N/A | 300 | Odense University HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05255471 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.(MITO 35B) | recruiting | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01763125 | Establishment of a Tumor Bank for Blood Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 4 | Mar 23, 2023 | clinicaltrials |
| NCT01789229 | Establishment of a Tumor Bank for Tissue Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 3 | Mar 23, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05607329 | Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial | recruiting | N/A | 400 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05551208 | Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | recruiting | Phase 2 | 42 | Chongqing University Cancer HospitalOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05030805 | Transcriptional Map of Ovarian Cancer at the Single Cell Level(Ova-seq) | recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04520074 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | recruiting | Phase 3 | 590 | Fudan UniversityOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05450055 | Intraperitoneal Lidocaine in Ovarian Cancer Surgery | not yet recruiting | N/A | 60 | Peking University Third HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT03983226 | Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) | recruiting | Phase 2 | 167 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05242861 | Retrospective Study of Brachytherapy(RetroBT) | recruiting | — | 300 | Zhejiang Cancer HospitalOTHER | 1 | Feb 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 22, 2024source: clinicaltrials